Navigation Links
DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
Date:2/11/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 11, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the third closing in a private placement consisting of approximately 1.2 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.0 million. The total amount raised in the private placement is $7.9 million.

Charles Vista, LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.  The maximum offering in the Private Placement consisted of 9,375,000 units for gross proceeds of $7.5 million.  In addition, the placement agent has been granted an over-allotment option of up to 3,125,000 units to cover over-subscriptions for additional gross proceeds of up to $2.5 million.  The over-allotment option is being exercised in part in connection with today's closing.

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com;   
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2019)... (PRWEB) , ... October 17, 2019 , ... The findings ... lung illness in the individuals studied could be caused by toxic chemicals rather than ... Severe Pulmonary Illness Associated With E-Cigarette Use (Vaping): A Report of Eight Cases ,” ...
(Date:10/15/2019)... (PRWEB) , ... October 14, ... ... VALIDATE® LP2 linearity and calibration verification kit, for Roche cobas® analyzers, Order ... and Apolipoprotein B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and ...
(Date:10/15/2019)... ... ... Twiggy Bean, Ph.D., wanted to educate others about the divorce bullying epidemic ... and become truly child focused. This objective prompted her to write “Divorce Bullying: An ... Don’t be a divorce bully!” (published by Balboa Press), a guidebook that serves as ...
Breaking Medicine Technology:
(Date:10/10/2019)... ... October 10, 2019 , ... In attendance at this year’s ... hear the significant results of an independent study presented by researchers from the ... study poster entitled “The Acute Effects of Citrulline Malate and Bonded Arginine Silicate ...
(Date:10/8/2019)... ... 2019 , ... What unique insights can three former Surgeons General of the ... the nation? That question will be answered at ICAA 2019: Shaping the Future of ... event will take place October 10-12, 2019, at the Gaylord Palms Resort and Convention ...
(Date:10/8/2019)... ... October 08, 2019 , ... In Vitro Sciences (IVS), ... Fertility Care (AFC), an advanced reproductive services (RE) facility operating in the greater ... RE services to expectant families throughout Arizona and the greater Southwest. , This ...
(Date:10/8/2019)... ... , ... Cognosante has been awarded a contract to continue ... Referrals and Authorizations program. The new task order will allow Cognosante ... enterprise-wide system used by community care staff to generate referrals and authorizations for ...
(Date:10/8/2019)... ... October 08, 2019 , ... As ... samples, Meiqing Shi, associate professor with the University of Maryland Department of Veterinary ... published in Nature Communications, Shi and his lab have discovered a new pathway ...
Breaking Medicine News(10 mins):